Tagged with generic

Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…

Generic Medicines Industry Association To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA is the lobby group for the generic medicines industry in Australia, working with all relevant stakeholders, such as government, prescribers,…

Biocon If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage in an infrastructure deficient Bangalore. Both India and Biocon have come a long way since then. How different is the…

British Generic Manufacturers Association (BGMA) Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic medicines, can you please explain the success of generic medicines in the UK? The important aspect about the UK, which…

Philippines In an exclusive interview, Benjamin Liuson, president of The Generics Pharmacy in the Philippines on the company’s illustrious history, remarkable growth, and increasing acceptance of generics more generally in the Philippines. The Generics Pharmacy originated from a family business and you are the visionary who transformed it into what it…

France Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in biosimilars, becoming a pioneer in a fast-growing niche. How have these two steps helped reshape Sandoz internally? With the creation…

generics “The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make hard decisions.” Until now, generics prescriptions were limited by strong links between innovators and doctors, and price alignment trends reducing…